Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Lancet
    July 2026
  1. WIYSONGE CS, Iwu-Jaja C
    The African Medicines Agency: time for integration with the African Vaccine Regulatory Forum.
    Lancet. 2026;408:121-122.
    >> Share

    June 2026
  2. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    >> Share

  3. PORTNOY A, Burger EA
    HPV vaccination and early declines in cervical cancer deaths.
    Lancet. 2026 Jun 17:S0140-6736(26)01024-X. doi: 10.1016/S0140-6736(26)01024.
    >> Share

  4. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    >> Share

  5. MEYER M, Kuzmin IV, Dews EA, Hyde MA, et al
    Single-dose mRNA vaccines against Andes hantavirus.
    Lancet. 2026 Jun 10:S0140-6736(26)01124-4. doi: 10.1016/S0140-6736(26)01124.
    >> Share

  6. WHITEMAN M, Tundang R, Maybarduk P, Abdullah H, et al
    How CEPI can enhance global vaccine equity and transparency.
    Lancet. 2026 Jun 8:S0140-6736(26)01137-2. doi: 10.1016/S0140-6736(26)01137.
    >> Share

    May 2026
  7. GAYTHORPE KAM, Li X, Shankar M, Hartner AM, et al
    Quantifying relative health impact across Gavi, the Vaccine Alliance's portfolio in 117 countries at the subregional level: a modelling study.
    Lancet. 2026;407:1941-1952.
    >> Share

  8. OSEI I, Wutor BM
    Vaccine impact in Gavi-supported countries: balancing evidence with policy needs.
    Lancet. 2026;407:1895-1897.
    >> Share

  9. MWAPASA V, Asante KP, Milligan P, Akech S, et al
    Impact of introducing RTS,S/AS01(E) malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme.
    Lancet. 2026;407:1796-1808.
    >> Share

  10. MCCLOSKEY B, Petersen E, Azhar EI, Zumla A, et al
    Meningococcal B resurgence in the UK: implications for updating global vaccine strategies.
    Lancet. 2026 May 8:S0140-6736(26)00863-9. doi: 10.1016/S0140-6736(26)00863.
    >> Share

  11. BRISSON M, Drolet M, Gingras G, Laprise JF, et al
    Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
    Lancet. 2026;407:1726-1737.
    >> Share

  12. CLIFFORD GM
    HPV vaccine scale-up is key to curb rising cervical cancer inequalities.
    Lancet. 2026;407:1662-1663.
    >> Share

    April 2026
  13. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    >> Share

  14. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    >> Share

  15. MCLELLAN F
    Amadou Sall: virologist committed to vaccine equity.
    Lancet. 2026;407:1590.
    >> Share

  16. NELSON NP, Ward JW
    Hepatitis A prevention in the USA depends on routine universal childhood vaccination.
    Lancet. 2026 Apr 22:S0140-6736(26)00510-6. doi: 10.1016/S0140-6736(26)00510.
    >> Share

  17. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    >> Share

  18. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    >> Share

    January 2026
  19. POLLARD AJ, Plotkin S
    A risk to child health: confusion and concern over changes to US vaccine policy.
    Lancet. 2026 Jan 20:S0140-6736(26)00090-5. doi: 10.1016/S0140-6736(26)00090.
    >> Share

  20. KIMATHI D, Juan-Giner A, Bob NS, Orindi B, et al
    Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial.
    Lancet. 2026 Jan 13:S0140-6736(25)02069-0. doi: 10.1016/S0140-6736(25)02069.
    >> Share

  21. TURTLE L
    Yellow fever vaccine minimum fractional dosing does not extend to infants.
    Lancet. 2026 Jan 13:S0140-6736(25)02364-5. doi: 10.1016/S0140-6736(25)02364.
    >> Share

  22. PALMIERI C, Tafuri S
    Vaccine hesitancy: an evolving challenge.
    Lancet. 2026 Jan 12:S0140-6736(25)02601-7. doi: 10.1016/S0140-6736(25)02601.
    >> Share

  23. WHITAKER M, Elliott J, Gerard-Ursin I, Cooke GS, et al
    Profiling vaccine attitudes and subsequent uptake in 1.1 million people in England: a nationwide cohort study.
    Lancet. 2026 Jan 12:S0140-6736(25)01912-9. doi: 10.1016/S0140-6736(25)01912.
    >> Share

  24. VAN GEERTRUYDEN JP, Lariviere Y, Zola Matuvanga T, Van Damme P, et al
    Ebola and health-care providers: the case for preventive vaccination.
    Lancet. 2026 Jan 12:S0140-6736(25)02459-6. doi: 10.1016/S0140-6736(25)02459.
    >> Share

  25. DWEK RA, Feldmann M, Fotinou C, Zitzmann N, et al
    If vaccines falter, broad-spectrum antivirals provide a global shield.
    Lancet. 2026;407:25-26.
    >> Share

    December 2025
  26. HAEUSER E, Hay SI, Mosser JF
    Population size and vaccination rates for zero-dose estimates - Authors' reply.
    Lancet. 2025;406:2627-2628.
    >> Share

  27. KUMARI N, Shridevi K, Katkuri S, Subudhi S, et al
    Population size and vaccination rates for zero-dose estimates.
    Lancet. 2025;406:2626-2627.
    >> Share

    November 2025
  28. YADAV PD, Sahay RR
    Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus vaccine in adults.
    Lancet. 2025 Nov 14:S0140-6736(25)02277-9. doi: 10.1016/S0140-6736(25)02277.
    >> Share

  29. FRENCK RW JR, Naficy A, Feser J, Dickey MP, et al
    Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
    Lancet. 2025 Nov 14:S0140-6736(25)01390-X. doi: 10.1016/S0140-6736(25)01390.
    >> Share

    October 2025
  30. JOHANSEN ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, et al
    Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
    Lancet. 2025 Oct 17:S0140-6736(25)01742-8. doi: 10.1016/S0140-6736(25)01742.
    >> Share

  31. DE SANTIS M, Palou Redorta J, Nishiyama H, Krawczynski M, et al
    Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
    >> Share

  32. HENDRICK J, Raqib R, Noor Z, Faruque ASG, et al
    Shigellosis.
    Lancet. 2025;406:1508-1519.
    >> Share

    September 2025
  33. KUEHN R, Rahden P, Hussain HS, Karkey A, et al
    Enteric (typhoid and paratyphoid) fever.
    Lancet. 2025;406:1283-1294.
    >> Share

    August 2025
  34. LEE K, Kohler J
    Good governance essential to expanding vaccine capacity and strengthening public trust.
    Lancet. 2025 Aug 29:S0140-6736(25)01681-2. doi: 10.1016/S0140-6736(25)01681.
    >> Share

  35. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    >> Share

  36. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    >> Share

  37. KULKARNI PS, Potey AV, Kapse D, Bhamare C, et al
    Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.
    Lancet. 2025;406:627-635.
    >> Share

  38. WAGNER J
    Respiratory syncytial virus vaccine effectiveness.
    Lancet. 2025;406:599.
    >> Share

  39. PAYNE AB, Mitchell PK, Watts JA, Link-Gelles R, et al
    Respiratory syncytial virus vaccine effectiveness - Authors' reply.
    Lancet. 2025;406:599-600.
    >> Share

    July 2025
  40. LARSON HJ, Piatek SJ
    A crisis of credibility: the global cost of US vaccine misinformation.
    Lancet. 2025 Jul 30:S0140-6736(25)01495-3. doi: 10.1016/S0140-6736(25)01495.
    >> Share

    June 2025
  41. FANG H
    Strengthening global routine childhood vaccination.
    Lancet. 2025 Jun 24:S0140-6736(25)01278-4. doi: 10.1016/S0140-6736(25)01278.
    >> Share


  42. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    >> Share

  43. PAIL O, Lin MJ, Anagnostou T, Brown BD, et al
    Cancer vaccines and the future of immunotherapy.
    Lancet. 2025 Jun 17:S0140-6736(25)00553-7. doi: 10.1016/S0140-6736(25)00553.
    >> Share

  44. HIRANI K, Rwebembera J, Webb R, Beaton A, et al
    Acute rheumatic fever.
    Lancet. 2025;405:2164-2178.
    >> Share

  45. LARSON H
    Vaccination: a changing political, scientific, and personal landscape.
    Lancet. 2025 Jun 5:S0140-6736(25)01193-6. doi: 10.1016/S0140-6736(25)01193.
    >> Share

    May 2025
  46. ATERE AO, Mustapha FB, Mustapha MJ
    Logistics of the malaria vaccine roll-out in Nigeria.
    Lancet. 2025;405:1815.
    >> Share

    April 2025
  47. MARQUES ETA, Burke DS
    Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine.
    Lancet. 2025;405:1314-1315.
    >> Share

  48. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    >> Share

    March 2025
  49. RICHARDSON JS, Anderson DM, Mendy J, Tindale LC, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00345-9. doi: 10.1016/S0140-6736(25)00345.
    >> Share

  50. TINDALE LC, Richardson JS, Anderson DM, Mendy J, et al
    Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2025 Mar 27:S0140-6736(25)00372-1. doi: 10.1016/S0140-6736(25)00372.
    >> Share

  51. MENSAH AA, Whitaker H, Andrews NJ, Watson CH, et al
    Early impact of RSV vaccination in older adults in England.
    Lancet. 2025 Mar 24:S0140-6736(25)00346-0. doi: 10.1016/S0140-6736(25)00346.
    >> Share

  52. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    >> Share

  53. ALVES L
    Brazil hopes for new vaccine to combat dengue.
    Lancet. 2025;405:770.
    >> Share

    February 2025
  54. PRASAD A
    Sarah Blagden: designing vaccines for cancer prevention.
    Lancet. 2025;405:613.
    >> Share

  55. NEUPANE D, Jaiswal LS, Koirala S
    Nepal set to launch historic HPV vaccination programme.
    Lancet. 2025;405:375.
    >> Share

    January 2025
  56. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    >> Share

  57. DATOO MS, Hill AVS, Beaumont E, Bradley J, et al
    The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
    Lancet. 2025;405:299-301.
    >> Share

  58. AABY P, Bjorkman A, Schapira A, Benn CS, et al
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    >> Share

  59. OBARO S, Mokuolu O, Michelow IC
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    >> Share

  60. LI Y, Liu G
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:298-299.
    >> Share

  61. IMPOUMA B, Adidja A, Mboussou F, Cabore J, et al
    Malaria vaccine introduction in Africa: progress and challenges.
    Lancet. 2025 Jan 21:S0140-6736(24)02841-1. doi: 10.1016/S0140-6736(24)02841.
    >> Share

  62. DZAU V, Hatchett R, Bishen S, Kaseya J, et al
    The time for regionalised vaccine manufacturing has arrived.
    Lancet. 2025 Jan 14:S0140-6736(25)00050-9. doi: 10.1016/S0140-6736(25)00050.
    >> Share

    December 2024
  63. TONY YANG Y
    The perils of RFK Junior's anti-vaccine leadership for public health.
    Lancet. 2024 Dec 18:S0140-6736(24)02603-5. doi: 10.1016/S0140-6736(24)02603.
    >> Share

    November 2024
  64. INO H, Takimoto Y, Nakazawa E
    Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue.
    Lancet. 2024;404:1922-1923.
    >> Share

    October 2024
  65. PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al
    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
    Lancet. 2024;404:1547-1559.
    >> Share

  66. BRANDA F, Oh J, Acharya KP, Yon DK, et al
    Human vaccination for highly pathogenic avian influenza.
    Lancet. 2024;404:1518-1519.
    >> Share

  67. BRANCHE AR
    Real-world effectiveness studies of the benefit of RSV vaccines.
    Lancet. 2024;404:1498-1500.
    >> Share

  68. ADEPOJU P
    Rwandan Marburg outbreak sparks vaccine efforts.
    Lancet. 2024;404:1389.
    >> Share

  69. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    >> Share

  70. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    >> Share

    September 2024
  71. PHUYAL S, Acharya KP, Yon DK
    Antibody titres after vaccination: a missing key to rabies control.
    Lancet. 2024;404:1192-1193.
    >> Share

  72. SALEEM SM, Jan SS
    Operationalising the One Health approach for rabies elimination.
    Lancet. 2024;404:1191-1192.
    >> Share

  73. ADEPOJU P
    Vaccination under way as mpox cases continue to rise.
    Lancet. 2024;404:1184.
    >> Share

  74. MAZUR NI, Caballero MT, Nunes MC
    Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.
    Lancet. 2024;404:1143-1156.
    >> Share

  75. WALDMAN R, Steinglass R, Nieburg P
    An urgent case for measles vaccination in Gaza.
    Lancet. 2024 Sep 20:S0140-6736(24)02076-2. doi: 10.1016/S0140-6736(24)02076.
    >> Share

  76. PECENKA C, Sparrow E, Feikin DR, Srikantiah P, et al
    Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Lancet. 2024 Sep 6:S0140-6736(24)01699-4. doi: 10.1016/S0140-6736(24)01699.
    >> Share

  77. NTUMBA HCK, Mandja BM
    Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination.
    Lancet. 2024 Sep 2:S0140-6736(24)01806-3. doi: 10.1016/S0140-6736(24)01806.
    >> Share

    August 2024
  78. ZHONG L, Zhao Q, Zeng MS, Zhang X, et al
    Prophylactic vaccines against Epstein-Barr virus.
    Lancet. 2024;404:845.
    >> Share

  79. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    >> Share

  80. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    >> Share

  81. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    >> Share

    July 2024
  82. ADEPOJU P
    African mpox surges show lack of vaccine access.
    Lancet. 2024;404:18.
    >> Share

    June 2024
  83. LI P, Meng Z, Zhou Z, Zhong Z, et al
    Therapeutic vaccines for Epstein-Barr virus: a way forward.
    Lancet. 2024;403:2779-2780.
    >> Share

  84. HO A, Galgut O, Faustini S, Peters N, et al
    Implications of suboptimal measles immunity in UK health-care workers.
    Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011.
    >> Share

  85. SAMARASEKERA U
    African vaccine manufacturing scheme to boost production.
    Lancet. 2024;403:2579-2580.
    >> Share

  86. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    >> Share

    May 2024
  87. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    >> Share

  88. ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al
    Cofinancing immunisation through national health insurance.
    Lancet. 2024;403:1983-1984.
    >> Share

  89. SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al
    Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
    Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850.
    >> Share

    April 2024
  90. COULBORN RM, Danet C, Alsalhani A
    Measles and rubella vaccine microneedle patch: new hope to reach the unreached children.
    Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749.
    >> Share

  91. ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al
    A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
    Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532.
    >> Share

  92. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    >> Share

  93. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
    Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
    Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
    >> Share

  94. DAUBENBERGER CA, Silva JC
    First-generation malaria vaccine successfully implemented in three African countries.
    Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
    >> Share

    March 2024
  95. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  96. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  97. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  98. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    >> Share

  99. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  100. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    >> Share

    February 2024
  101. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    >> Share

  102. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016